SCHEMBL4720801

SCHEMBL4720801

CCOC(=O)c1csc(Nc2cc(Cl)ccc2OC)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.61
ANO1 Q5XXA6 1/20 0.61
MAPK1 P28482 1/20 0.61
NPSR1 Q6W5P4 1/20 0.60
HSD17B10 Q99714 1/20 0.60
MEN1 O00255 10/20 0.59
KMT2A Q03164 10/20 0.59
ALDH1A1 P00352 8/20 0.59
MAPT P10636 8/20 0.59
HPGD P15428 6/20 0.59
KDM4E B2RXH2 3/20 0.59
L3MBTL1 Q9Y468 1/20 0.56
TSHR P16473 1/20 0.55
EGFR P00533 1/20 0.55
CFTR P13569 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NR2F2 P24468 1/20 0.54
HTT P42858 1/20 0.54
POLB P06746 1/20 0.53
PTGER1 P34995 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21708023 0.88 LMNA (0.61) LMNAMAPK1NPSR1HSD17B10MEN1
SCHEMBL4723608 0.87 LMNA (0.59) LMNAANO1MAPK1NPSR1HSD17B10
SCHEMBL4722539 0.87 L3MBTL1 (0.58) LMNAANO1MAPK1NPSR1HSD17B10
SCHEMBL4915995 0.85 MEN1 (0.58) LMNANPSR1MEN1KMT2AALDH1A1
SCHEMBL5125850 0.85 PTGER1 (0.76) LMNAANO1MAPK1NPSR1HSD17B10
SCHEMBL5035870 0.82 LMNA (0.71) LMNAANO1MAPK1NPSR1HSD17B10
SCHEMBL21708026 0.81 SMN1; SMN2 (0.59) LMNAMAPK1NPSR1HSD17B10MEN1
SCHEMBL5041112 0.80 EGFR (0.73) LMNAANO1MAPK1NPSR1MEN1
SCHEMBL3038926 0.79 LMNA (0.64) LMNAANO1MAPK1NPSR1HSD17B10
SCHEMBL789722 0.78 MAPT (0.73) LMNAMAPK1NPSR1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine UNIVERSITY OF HEIDELBERG (DE) 2020-02-27 US disclosed
EP-3611256-A1 APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE Universität Heidelberg (DE) 2020-02-19 EP disclosed
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders GLAXO GROUP LIMITED (GB) 2008-08-28 US disclosed
EP-1874776-A1 OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2008-01-09 EP disclosed
WO-2006114274-A1 OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS GLAXO GROUP LIMITED (GB) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207708-A1 Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders PTGER1, PTGER2, PTGER4 LMNA 2542/4885ANO1 2476/4885MAPK1 2517/4885
US-20200062719-A1 Application of Imidazopyridine Derivatives in Regenerative Medicine DOT1L, NSD1, KDM3A LMNA 3592/4885ANO1 1810/4885MAPK1 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.